(3R, 4R)-trans-3, 4-diarylchroman derivatives and a method for the prevention and/or treatment of estrogen dependent diseases
    71.
    发明申请
    (3R, 4R)-trans-3, 4-diarylchroman derivatives and a method for the prevention and/or treatment of estrogen dependent diseases 失效
    (3R,4R) - 反-3,4-二芳基苯并二氢吡喃衍生物和预防和/或治疗雌激素依赖性疾病的方法

    公开(公告)号:US20050070597A1

    公开(公告)日:2005-03-31

    申请号:US10677116

    申请日:2003-09-30

    CPC classification number: C07D311/58

    Abstract: The present invention relates to compounds of the formula I in which substituents R2 and R3 are arranged in trans-configuration: wherein: R1 is H or C1-C6 alkyl; C3-C7 cycloalkyl; R2 is phenyl, optionally substituted with 1 to 5 substituents independently selected from the group comprising OH, C1-C6-alkyl, halogen, nitro, cyano, SH, SR4, trihalo-C1-C6-alkyl, C1-C6-alkoxy and phenyl, wherein R4 is C1-C6 alkyl; R3 is phenyl substituted with OR5 wherein R5 has the formula (II), (III) or (IV) wherein Y is chosen from NHR4, NR42, NHCOR4, NHSO2R4, CONHR4, CONR4, CONR42, COOH, COOR4, SO2R4, SOR4, SONHR4, SONR42, a C3-C7 heterocyclic ring, saturated or unsaturated, containing one or two heteroatoms independently selected from the group consisting of O, S and N, optionally being substituted with 1 to 3 substituents independently selected from the group comprising H, OH, halogen, nitro, cyano, SH, SR4, trihalo-C1-C6-alkyl, C1-C6-alkyl and C1-C6-alkoxy, preferably NHR4, NR24, or a nitrogen heterocycle, wherein R4 is as defined above, and the esters, ethers, and salts of the compounds of formula I, optionally along pharmaceutically acceptable excipients, a process for the preparation of the same, and a method of preventing and/or treating estrogen-related disease conditions in a subject using compounds of formula 1, or its salts, optionally along with pharmaceutically acceptable excipients.

    Abstract translation: 本发明涉及式I化合物,其中取代基R 2和R 3以反式构型排列:其中:R 1是H或C 1 -C 6烷基; C3-C7环烷基; R 2是苯基,任选地被1至5个独立地选自OH,C 1 -C 6 - 烷基,卤素,硝基,氰基,SH,SR 4, - 3卤代-C 1 -C 6烷基,C 1 C 1-6 - 烷氧基和苯基,其中R 4是C 1 -C 6烷基; R 3是被OR 5取代的苯基,其中R 5具有式(II),(III)或(IV),其中Y选自NHR 4,NR 4,NHCOR 4 >,NHSO 2 R 4,CONHR 4,CONR 4,CONR 4,COOH,COOR 4,SO 2 R 4,SOR 4,SONHR 4,SONR 4 饱和或不饱和的C3-C7杂环,其含有一个或两个独立地选自O,S和N的杂原子,任选被1至3个独立地选自H,OH,卤素, 硝基,氰基,SH,SR 4,三卤代-C 1 -C 6烷基,C 1 -C 6烷基和C 1 -C 6烷氧基,优选NH 4,NR 2 4或氮杂环, 4>如上所定义,并且式I化合物的酯,醚和盐,任选地沿着药学上可接受的赋形剂,其制备方法,以及预防和/或治疗雌激素相关疾病的方法 使用式1化合物的受试者的条件,或其盐,任选地与药物 lly可接受的赋形剂。

    Atomic layer deposition of cobalt from cobalt metallorganic compounds
    72.
    发明授权
    Atomic layer deposition of cobalt from cobalt metallorganic compounds 有权
    来自钴金属有机化合物的钴的原子层沉积

    公开(公告)号:US06527855B2

    公开(公告)日:2003-03-04

    申请号:US09974178

    申请日:2001-10-10

    CPC classification number: C23C16/18

    Abstract: Cobalt thin films were prepared by atomic layer deposition (ALD). The precursor cobalt(II) acetylacetonate [Co(C5H7O2)2] was used to selectively deposit films onto iridium substrates using hydrogen reduction. Cobalt growth was observed on SiO2, silicon, fluorinated silica glass (FSG), and tantalum when silane was used as a reducing agent.

    Abstract translation: 通过原子层沉积(ALD)制备钴薄膜。 使用乙酸丙酮前体钴(II)[Co(C 5 H 7 O 2)2]使用氢还原将膜选择性地沉积在铱底物上。 当使用硅烷作为还原剂时,在SiO2,硅,氟化石英玻璃(FSG)和钽上观察到钴生长。

    Lightwave communication systems using semiconductor optical amplifiers
    73.
    发明授权
    Lightwave communication systems using semiconductor optical amplifiers 有权
    使用半导体光放大器的光波通信系统

    公开(公告)号:US06473212B1

    公开(公告)日:2002-10-29

    申请号:US09253259

    申请日:1999-02-19

    CPC classification number: H04B10/296 H04B10/2914

    Abstract: Substantially error-free communications is achieved in an optical communication system that includes optical amplifiers by detecting bits transmitted in the amplified optical signal using a detection threshold that is derived as a function of a maximum power level associated with a first bit value, e.g., bit “0”, and a minimum power level associated with a second bit value, e.g., bit “1”. Importantly, this detection scheme can be used to accurately detect bit patterns in the amplified signal even in the presence of nonlinear distortions caused by gain variations, such as inter-modal distortion and saturation induced crosstalk. In a wavelength division multiplexed (WDM) system comprising semiconductor optical amplifiers, for example, the detection threshold can be set at a level corresponding to PTOTAL/2N, where PTOTAL represents the total power in the WDM signal and N represents the number of optical channels in the WDM signal. According to another aspect of the invention, the effect of gain fluctuations becomes smaller as the number of channels increase. In particular, a smoothing effect is realized for the total effective saturation power as gain variations decrease as a function of an increase in the number of channels. As such, the performance of a semiconductor optical amplifier according to the principles of the invention approaches the linear performance of fiber amplifiers as the number of channels increases.

    Abstract translation: 在包括光放大器的光通信系统中实现基本无差错的通信,所述光通信系统使用检测阈值来检测放大的光信号中发送的位,所述检测阈值作为与第一位值相关联的最大功率电平的函数导出,例如位 “0”,以及与第二位值相关联的最小功率电平,例如位“1”。 重要的是,即使存在由诸如模态间失真和饱和感应串扰的增益变化引起的非线性失真,该检测方案也可用于精确地检测放大信号中的位模式。 在包括半导体光放大器的波分复用(WDM)系统中,例如,检测阈值可以被设置在与PTOTAL / 2N相对应的电平,其中PTOTAL表示WDM信号中的总功率,N表示光信道数 在WDM信号中。 根据本发明的另一方面,增益波动的效果随着信道数量的增加而变小。 特别地,当增益变化随着通道数量的增加而减小时,实现总有效饱和功率的平滑效果。 因此,根据本发明原理的半导体光放大器的性能随着信道数量的增加而接近光纤放大器的线性性能。

    Noise figure in optical amplifiers with a split-band architecture
    74.
    发明授权
    Noise figure in optical amplifiers with a split-band architecture 失效
    具有分频架构的光放大器的噪声系数

    公开(公告)号:US6049418A

    公开(公告)日:2000-04-11

    申请号:US89863

    申请日:1998-06-03

    Abstract: A wideband optical amplifier employs split-band architecture in which an optical signal passes through a common amplification stage and is then split to pass through parallel gain stages, each of which may be optimized for a particular band being traversed. A broadband grating reflector is used after the input gain section to reflect the signals of one of the bands so that they again will pass through the common input gain section before passing through gain section of the split structure dedicated to their particular wavelength. Meanwhile, the other signals pass through the reflector and move on through the gain section pertinent to their wavelength.

    Abstract translation: 宽带光放大器采用分波段结构,其中光信号通过公共放大级,然后被分割以通过并行增益级,其中的每一级可以针对被遍历的特定频带进行优化。 在输入增益部分之后使用宽带光栅反射器以反射其中一个频带的信号,使得它们在通过专用于其特定波长的分割结构的增益部分之前再次通过公共输入增益部分。 同时,其他信号通过反射器并且通过与它们的波长有关的增益部分。

    Asphaltenes as sacrificial agents in oil recovery processes
    77.
    发明授权
    Asphaltenes as sacrificial agents in oil recovery processes 失效
    作为油回收过程中的重要代理人

    公开(公告)号:US4113013A

    公开(公告)日:1978-09-12

    申请号:US738494

    申请日:1976-11-04

    CPC classification number: C09K8/607

    Abstract: A process for producing petroleum from subterranean formations is disclosed wherein production from the formation is obtained by driving a fluid from an injection well to a production well. The process involves injecting into the formation via the injection well asphaltenes as sacrificial agents to inhibit the deposition of chemical recovery agents such as surfactant on the reservoir matrix. Normally the process would be carried out by first injecting the asphaltenes into the formation through the injection well and following them with a chemical recovery agent. The chemical recovery agent would then be followed by a drive fluid such as water to push the materials to the production well.

    System for distending body tissue cavities by continuous flow irrigation
    79.
    发明授权
    System for distending body tissue cavities by continuous flow irrigation 有权
    通过连续流动灌溉膨胀身体组织腔的系统

    公开(公告)号:US08652089B2

    公开(公告)日:2014-02-18

    申请号:US10548950

    申请日:2004-07-21

    Abstract: The present invention provides a system and a method for distending a body tissue cavity of a subject by continuous flow irrigation such that minimal or negligible fluid turbulence is present inside the cavity, such that any desired cavity pressure can be created and maintained for any desired outflow rate. The present invention also provides a method for accurately determining the rate of fluid loss, into the subject's body system, during any endoscopic procedure without utilizing any deficit weight or fluid volume calculation or flow rate sensor. The system and the methods of the present invention described above can be used in any endoscopic procedure requiring continuous flow irrigation few examples of such endoscopic procedures being hysteroscopic surgery, arthroscopic surgery, trans uretheral surgery, endoscopic surgery of the brain and endoscopic surgery of the spine.

    Abstract translation: 本发明提供一种系统和方法,用于通过连续流动冲洗来膨胀受试者的身体组织腔,使得在腔内存在最小或可忽略的流体湍流,使得可以产生任何期望的腔压力并保持任何期望的流出 率。 本发明还提供了一种用于在任何内窥镜程序期间精确地确定流体损失进入受检者体内系统的方法,而不使用任何赤字重量或流体体积计算或流量传感器。 上述本发明的系统和方法可用于需要连续流动灌洗的任何内窥镜程序中,这种内窥镜手术的例子是宫腔镜手术,关节镜手术,经皮穿刺手术,脑内窥镜手术和脊柱内窥镜手术 。

Patent Agency Ranking